Elvina Almuradova/X
Jun 4, 2025, 07:03
Elvina Almuradova: ATOMIC Trial – Atezolizumab + FOLFOX Cuts Stage III Colon Cancer Recurrence by 50%
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on X:
“ASCO25, ATOMIC trial
In stage III dMMR colon cancer, adding atezolizumab to FOLFOX
Cut recurrence by 50%
3-yr DFS: 86.4% vs 76.6%
HR: 0.50
Could this approach also benefit patients with high-risk stage II colon cancer?”
Title: Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)
Authors: Frank A. Sinicrope, Fang-Shu Ou, Tyler Zemla, Andrew B. Nixon, Kabir Mody, Alexandra Levasseur, Amylou C. Dueck, Asha R. Dhanarajan, Christopher Hanyoung Lieu, Deirdre Jill Cohen, Federico Innocenti, Robert J. Behrens, Walter Peters, Nicolas Sommer, Eileen Mary O’Reilly, and Jeffrey A. Meyerhardt
Read the Full Article.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 17:02
Jun 4, 2025, 16:33
Jun 4, 2025, 16:33
Jun 4, 2025, 15:56